Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13762174 | 1.00 | CHRNB2 (0.37) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL8232225 | 1.00 | CHRNB2 (0.37) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL30872937 | 1.00 | CHRNB2 (0.37) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL2055320 | 1.00 | CHRNB2 (0.37) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL2108480 | 1.00 | CHRNB2 (0.37) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL7721751 | 1.00 | CHRNB2 (0.37) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL2055326 | 1.00 | CHRNB2 (0.37) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL1569371 | 1.00 | CHRNB2 (0.37) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL21442028 | 1.00 | CHRNB2 (0.37) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Hydrochloric Acid SCHEMBL680110 | 0.98 | CHRNB2 (0.36) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116640084-A | Preparation process of (1R, 5S) -6, 6-dimethyl-3-azabicyclo [3.1.0] hexane | 浙江司太立制药股份有限公司 | 2023-08-25 | — | — | CN | disclosed |
| WO-2023023631-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. (US) | 2023-02-23 | — | — | WO | disclosed |
| US-11541034-B2 | Nitrile-containing antiviral compounds | PFIZER INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-11452711-B2 | Nitrile-containing antiviral compounds | PFIZER INC. (US) | 2022-09-27 | — | — | US | disclosed |
| US-11351149-B2 | Nitrile-containing antiviral compounds | PFIZER INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20110286969-A1 | DEUTERATED COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS | SCHERING CORPORATION (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110286969-A1 | DEUTERATED COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS | SCHERING CORPORATION (US) | 2011-11-24 | — | — | US | disclosed |
| US-20070237818-A1 | Controlled-release formulation of HCV protease inhibitor and methods using the same | SCHERING CORPORATION | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11452711-B2 | Nitrile-containing antiviral compounds | ACE2, NOS2, EIF2AK2 | CHRNB2 4064/4885CHRNA4 4256/4885CHRNB4 4047/4885 |
| US-11541034-B2 | Nitrile-containing antiviral compounds | ACE2, NOS2, EIF2AK2 | CHRNB2 4064/4885CHRNA4 4256/4885CHRNB4 4047/4885 |
| US-11351149-B2 | Nitrile-containing antiviral compounds | ACE2, NOS2, EIF2AK2 | CHRNB2 4064/4885CHRNA4 4256/4885CHRNB4 4047/4885 |
| US-20110286969-A1 | DEUTERATED COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS | PEPD, PREP, ACE | CHRNB2 4874/4885CHRNA4 4857/4885CHRNB4 4876/4885 |
| US-20070237818-A1 | Controlled-release formulation of HCV protease inhibitor and methods using the same | CTRL, PEPD, PRCP | CHRNB2 4467/4885CHRNA4 4278/4885CHRNB4 4154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.